

Robert E Bristow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3674142/publications.pdf>

Version: 2024-02-01

90
papers

7,468
citations

87888

38
h-index

58581

82
g-index

90
all docs

90
docs citations

90
times ranked

5527
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2002, 20, 1248-1259.	1.6	1,933
2	Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2006, 103, 1070-1076.	1.4	344
3	Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2013, 130, 493-498.	1.4	338
4	Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2009, 112, 265-274.	1.4	318
5	A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. <i>Cancer</i> , 2000, 89, 1532-1540.	4.1	291
6	Survival Impact of Surgical Cytoreduction in Stage IV Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1999, 72, 278-287.	1.4	288
7	Disparities in Ovarian Cancer Care Quality and Survival According to Race and Socioeconomic Status. <i>Journal of the National Cancer Institute</i> , 2013, 105, 823-832.	6.3	213
8	The National Cancer Database report on advanced-stage epithelial ovarian cancer: Impact of hospital surgical case volume on overall survival and surgical treatment paradigm. <i>Gynecologic Oncology</i> , 2010, 118, 262-267.	1.4	193
9	Adherence to Treatment Guidelines for Ovarian Cancer as a Measure of Quality Care. <i>Obstetrics and Gynecology</i> , 2013, 121, 1226-1234.	2.4	191
10	Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. <i>Gynecologic Oncology</i> , 2003, 90, 519-528.	1.4	189
11	Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. <i>Gynecologic Oncology</i> , 2007, 104, 480-490.	1.4	181
12	Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 4059-4067.	1.5	166
13	Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining "optimal" residual disease. <i>Gynecologic Oncology</i> , 2012, 125, 483-492.	1.4	152
14	High-volume ovarian cancer care: Survival impact and disparities in access for advanced-stage disease. <i>Gynecologic Oncology</i> , 2014, 132, 403-410.	1.4	141
15	Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. <i>Gynecologic Oncology</i> , 2009, 115, 334-338.	1.4	139
16	Ovarian cancer in the United States: Contemporary patterns of care associated with improved survival. <i>Gynecologic Oncology</i> , 2015, 136, 11-17.	1.4	121
17	Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. <i>Gynecologic Oncology</i> , 2013, 128, 252-259.	1.4	115
18	Role of aggressive surgical cytoreduction in advanced ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 336.	2.2	110

#	ARTICLE	IF	CITATIONS
19	Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. <i>Journal of the American College of Surgeons</i> , 2003, 197, 565-574.	0.5	107
20	Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. <i>Gynecologic Oncology</i> , 2005, 99, 294-300.	1.4	100
21	Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. <i>Gynecologic Oncology</i> , 2014, 134, 60-67.	1.4	99
22	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPeritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations â€” Part I: Preoperative and intraoperative management. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2292-2310.	1.0	98
23	Impact of National Cancer Institute Comprehensive Cancer Centers on Ovarian Cancer Treatment and Survival. <i>Journal of the American College of Surgeons</i> , 2015, 220, 940-950.	0.5	94
24	Impact of Surgeon Specialty on Ovarian-Conserving Surgery in Young Females with an Adnexal Mass. <i>Journal of Adolescent Health</i> , 2006, 39, 411-416.	2.5	83
25	Centralization of care for patients with advanced-stage ovarian cancer. <i>Cancer</i> , 2007, 109, 1513-1522.	4.1	79
26	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPeritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations â€” Part II: Postoperative management and special considerations. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2311-2323.	1.0	79
27	Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 468.e1-468.e9.	1.3	73
28	Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. <i>Gynecologic Oncology</i> , 2006, 103, 709-713.	1.4	67
29	Salvage cytoreductive surgery for recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2006, 103, 281-287.	1.4	61
30	Recurrent micropapillary serous ovarian carcinoma. <i>Cancer</i> , 2002, 95, 791-800.	4.1	58
31	Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. <i>Gynecologic Oncology</i> , 2005, 99, 301-308.	1.4	55
32	Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 121-127.	1.4	49
33	Surgery for ovarian cancer: how to improve survival. <i>Lancet, The</i> , 2006, 367, 1558-1560.	13.7	46
34	Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2007, 106, 476-481.	1.4	45
35	Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a Tertiary Gynecologic Oncology Referral Center. <i>Gynecologic Oncology</i> , 2011, 122, 319-323.	1.4	44
36	Racial disparities in ovarian cancer surgical care: A population-based analysis. <i>Gynecologic Oncology</i> , 2011, 121, 364-368.	1.4	43

#	ARTICLE	IF	CITATIONS
37	A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature. American Journal of Obstetrics and Gynecology, 2015, 212, 717-724.	1.3	43
38	Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. American Journal of Obstetrics and Gynecology, 2014, 210, 78.e1-78.e9.	1.3	41
39	Ovarian cancer surgery in Maryland: volume-based access to care. Gynecologic Oncology, 2004, 93, 353-360.	1.4	37
40	Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: Operative technique and clinical outcome. Gynecologic Oncology, 2009, 114, 173-177.	1.4	37
41	Micropapillary Serous Ovarian Carcinoma: Surgical Management and Clinical Outcome. Gynecologic Oncology, 2002, 86, 163-170.	1.4	36
42	Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California. Environmental Research, 2017, 156, 388-393.	7.5	34
43	Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis. Journal of Clinical Oncology, 2022, 40, 1659-1670.	1.6	33
44	Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronateâ€“carboxymethylcellulose (HAâ€“CMC) barrier: A cost-effectiveness analysis. Gynecologic Oncology, 2007, 104, 739-746.	1.4	32
45	It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. Gynecologic Oncology, 2018, 151, 555-561.	1.4	29
46	Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: A Society of Gynecologic Oncology study. Gynecologic Oncology Reports, 2017, 22, 100-104.	0.6	28
47	Spatial analysis of advanced-stage ovarian cancer mortality in California. American Journal of Obstetrics and Gynecology, 2015, 213, 43.e1-43.e8.	1.3	25
48	Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2018, 149, 525-530.	1.4	24
49	Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer. Gynecologic Oncology, 2015, 139, 495-499.	1.4	23
50	Surgical management of recurrent ovarian cancer. Gynecologic Oncology, 2016, 142, 357-367.	1.4	23
51	Transverse colectomy in ovarian cancer surgical cytoreduction: Operative technique and clinical outcome. Gynecologic Oncology, 2008, 109, 364-369.	1.4	22
52	Analysis of Contemporary Trends in Access to High-Volume Ovarian Cancer Surgical Care. Annals of Surgical Oncology, 2009, 16, 3422-3430.	1.5	22
53	Surgical technique of <i>en bloc</i> pelvic resection for advanced ovarian cancer. Journal of Gynecologic Oncology, 2015, 26, 155.	2.2	22
54	Racialâ€“Ethnic and Socioeconomic Disparities in Guideline-Adherent Treatment for Endometrial Cancer. Obstetrics and Gynecology, 2021, 138, 21-31.	2.4	19

#	ARTICLE	IF	CITATIONS
55	A Review of Thoracic and Mediastinal Cytoreductive Techniques in Advanced Ovarian Cancer: Extending the Boundaries. <i>Annals of Surgical Oncology</i> , 2017, 24, 3700-3705.	1.5	18
56	Impact of hospital care volume on clinical outcomes of laparoscopic radical hysterectomy for cervical cancer. <i>Medicine (United States)</i> , 2018, 97, e13445.	1.0	17
57	Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 581.e1-581.e8.	1.3	15
58	Contribution of Geographic Location to Disparities in Ovarian Cancer Treatment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1318-1329.	4.9	15
59	The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 65.e1-65.e11.	1.3	14
60	Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention. <i>Gynecologic Oncology</i> , 2015, 138, 694-699.	1.4	13
61	An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 303-308.	0.6	13
62	Transdiaphragmatic cardiophrenic lymph node resection for Stage IV ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 762-763.	1.4	12
63	A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals. <i>Obstetrics and Gynecology</i> , 2020, 135, 328-339.	2.4	11
64	Ambient air pollution and ovarian cancer survival in California. <i>Gynecologic Oncology</i> , 2021, 163, 155-161.	1.4	11
65	Advanced cytoreductive surgery in gynecologic oncology. <i>Gynecologic Oncology</i> , 2009, 114, S1-S2.	1.4	10
66	Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis. <i>Gynecologic Oncology</i> , 2016, 143, 688-689.	1.4	9
67	Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study. <i>BMC Cancer</i> , 2018, 18, 800.	2.6	9
68	Guideline-adherent treatment, sociodemographic disparities, and cause-specific survival for endometrial carcinomas. <i>Cancer</i> , 2021, 127, 2423-2431.	4.1	9
69	Looking at cancer health disparities in gynecologic oncology in 2020. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 355-359.	2.0	9
70	Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 845-854.	2.5	7
71	Ovarian cancer in California: Guideline adherence, survival, and the impact of geographic location, 1996-2014. <i>Cancer Epidemiology</i> , 2020, 69, 101825.	1.9	7
72	Clinical commentary: Medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using a non-bevacizumab containing arm feasible in patients with recurrent cervical cancer?. <i>Gynecologic Oncology</i> , 2014, 134, 447-449.	1.4	6

#	ARTICLE	IF	CITATIONS
73	Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for laryngeal cancer. Laryngoscope, 2020, 130, 672-678.	2.0	5
74	In response to: Establishing evidence for change in ovarian cancer surgery – Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecologic Oncology, 2009, 115, 168-169.	1.4	4
75	The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers. Gynecologic Oncology, 2021, 163, 3-4.	1.4	4
76	Reply to W.R. Robinson. Journal of Clinical Oncology, 2012, 30, 1563-1564.	1.6	3
77	Surgical Management of Gynecologic Cancers. Surgical Oncology Clinics of North America, 2021, 30, 69-88.	1.5	3
78	Rectosigmoid resection by gynecologic oncologists versus colorectal surgeons: as long as it catches the mouse, does the color of the cat matter?. Journal of Gynecologic Oncology, 2021, 32, e51.	2.2	3
79	Extended left upper quadrant resection during primary cytoreductive surgery for Stage IV ovarian cancer. Gynecologic Oncology, 2016, 142, 378.	1.4	2
80	Incidence Rates of Gynecologic Cancers in the U.S. Active Duty Military Population. Military Medicine, 2020, 185, e1590-e1595.	0.8	2
81	Population-based analysis of National Comprehensive Cancer Network (NCCN) guideline adherence for patients with anal squamous cell carcinoma in California.. Journal of Clinical Oncology, 2021, 39, 1-1.	1.6	2
82	In Reply. Obstetrics and Gynecology, 2013, 122, 907.	2.4	1
83	Racial/Ethnic Disparities in Gynecological Cancer Screening, Treatment, and Survival. , 2016, , 151-166.		1
84	Borderline Tumors and Other Rare Epithelial Tumors of the Ovary. , 2006, , 447-454.		0
85	Neoadjuvant chemotherapy for ovarian cancer: pro versus con. Women's Oncology Review, 2007, 6, 27-35.	0.0	0
86	Volume-Based Trends in Parotid Surgery. Laryngoscope, 2010, 120, S32-S32.	2.0	0
87	–Kegel ball–induced vaginal cuff dehiscence following radical abdominal hysterectomy: Laparoscopically-assisted transvaginal retrieval. Gynecologic Oncology, 2012, 124, 170.	1.4	0
88	Cardiophrenic lymph node metastasis in low-grade serous ovarian adenocarcinoma. Gynecologic Oncology Reports, 2017, 19, 31-33.	0.6	0
89	Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer. Journal of Obstetrics and Gynaecology, 2020, 41, 1-6.	0.9	0
90	A panel of biomarkers to improve specificity in presurgical assessment of adnexal masses for risk of ovarian malignancy.. Journal of Clinical Oncology, 2013, 31, 5573-5573.	1.6	0